What is TRexBio?
Founded in 2018 and based in South San Francisco, California, TRexBio is at the forefront of leveraging cutting-edge computational biology tools, a focus on human tissue, and deep expertise in immunobiology. The company's powerful 'deep biology' discovery engine is designed to identify and characterize novel targets for therapeutic intervention. By mapping human tissue Treg behavior to disease processes, TRexBio aims to unlock new avenues for treating complex conditions such as cancer and inflammatory diseases, positioning itself as a key player in the biopharmaceutical innovation landscape.
How much funding has TRexBio raised?
TRexBio has raised a total of $303M across 4 funding rounds:
Series A
$85M
Not Disclosed
$84M
Series B
$84M
Other Financing Round
$50M
Series A (2022): $85M with participation from Alexandria Venture Investments, Johnson & Johnson Innovation, SV Health Investors, Eli Lilly, and Pfizer Ventures
Not Disclosed (2024): $84M led by Agent Capital and Delos Wealth Advisors
Series B (2024): $84M supported by Avego, Alexandria Venture Investments LLC Alexandria Venture Investments, Johnson & Johnson MedTech, Pfizer, Delos Capital, SV Health Investors, Agent Capital, Polaris Partners, and Eli Lilly and Company Pvt
Other Financing Round (2026): $50M featuring Balyasny Asset Management, Lilly, Johnson & Johnson Innovation, Delos Capital, Polaris Partners, Avego, Affinity Asset Advisors, Janus Henderson Investors, and SV Health Investors
Key Investors in TRexBio
Agent Capital
Agent Capital is a healthcare venture capital firm that invests in novel therapeutics and treatments aimed at addressing unmet patient needs. The firm collaborates with scientists, entrepreneurs, and investors to foster the development of innovative healthcare solutions across various stages of development.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors. The company uses deep research, advanced technology, and disciplined risk management to identify opportunities across financial markets.
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience.
What's next for TRexBio?
With substantial backing from prominent investors, TRexBio is poised for significant advancements in its therapeutic pipeline. The recent major strategic investment signals strong confidence in the company's scientific approach and market potential. This capital will likely fuel further research and development, enabling TRexBio to advance its lead candidates through preclinical and clinical stages. The company's focus on immunobiology and deep tissue insights suggests a strategic expansion into areas with high unmet medical needs, potentially leading to groundbreaking treatments and partnerships within the oncology and immunology sectors.
See full TRexBio company page
